Special Issue "Lysosomal Storage Disorders: Novel Concepts, Therapeutic Aspects and Beyond"
Deadline for manuscript submissions: closed (28 February 2017).
Interests: lysosomal storage disorders; vesicular trafficking; endosomal sorting; lysosome biogenesis; mitochondrial diseases; autoimmune disorders
Special Issues, Collections and Topics in MDPI journals
Special Issue in International Journal of Molecular Sciences: Molecular Features of Lysosomal Storage Disorders
Special Issue in International Journal of Molecular Sciences: Mitogen Activated Protein Kinases: Functions in Signal Transduction and Human Diseases
Special Issue in Cells: Metabolomics in Physiology and Diseases
Special Issue in Cells: Lysosomal Storage Disorders
Special Issue in International Journal of Molecular Sciences: Mitogen Activated Protein Kinases: Functions in Signal Transduction and Human Diseases 2.0
Topical Collection in Cells: Feature Papers in Cellular Pathology
Special Issue in Cells: Molecular and Cellular Mechanisms of Rare Diseases
Lysosomal storage disorders (LSDs) are a heterogeneous group of rare monogenic diseases that are characterized by aberrant lysosomes with storage material. These diseases frequently manifest as severe defects of the central nervous system, mental retardation and reduced life span. Most LSDs result from a deficiency of a single enzyme, whereas others are caused by mutations in non-enzymatic proteins. In the past couple of years, our knowledge about the pathogenesis and the molecular details of the genes involved has substantially increased. These findings have forced us to rethink some old central dogmas about these diseases and revealed novel aspects about the pathomechanisms. Importantly, novel therapy options have become available, or are under development, for some LSDs that were previously considered fatal.
The purpose of this Special Issue is to summarize our current understanding of LSDs and the involvement of various cellular pathways such as autophagy, neuroinflammation, microgliosis and signaling in their pathogenesis. We also highly welcome papers addressing all current and prospective therapies for LSDs, as well as novel concepts and hypotheses about these disorders, including their connections to more common diseases such as Alzheimer’s or Parkinson’s. We encourage the submission of review articles and original research papers of any length. Our aim is to provide a comprehensive update on LSDs, their pathomechanisms and therapy options.
Prof. Dr. Ritva Tikkanen
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- lysosomal storage disorders
- enzyme replacement
- gene therapy
- substrate reduction
- pharmacological chaperones